TPGS is known to activate both caspase-dependent and caspase-independent PCD in breast cancer cell lines, inducing the downregulation of Bcl-2, the translocation of AIF and Endo G to the cytosol and the cleavage of caspase-7 and PARP19. This evidence concerns the gene BCL2 and breast carcinoma.